9/12 5:30 pm - 8:30 pm
HBA presents 'Putting Academia-Industry Research Partnerships to Work.' Novartis, 1 Health Plaza, East Hanover, NJ more
9/24 4:00 pm - 6:00 pm
CURE presents healthcare investment banker Anthony Gibney of Leerink Swann. Yale Anlyan Center, 300 Cedar Street, New Haven more
10/1 4:00 pm - 6:00 pm
CURE/Yale BioHaven presents Trevi Therapeutics. Anlyan Center, 300 Cedar Street, New Haven. Watch for details.
10/8-9 12th annual BIO Investor Forum. The Palace Hotel, San Francisco more
10/15 6:00 pm - 9:30 pm
HBA presents Women's Healthcare Innovation and Leadership Showcase. Sanofi Campus, 55 Corporate Drive Auditorium, Bridgewater, NJ more
11/7 10:00 am - 3:00 pm
CT Innovation Summit. Mentor meetings, awards ceremony, and more. Co-sponsored by CURE. Oakdale Theater, Wallingford more
11/11-13 The BIO Convention in China. National Convention Center, Beijing more
12/3 5:45 pm - 7:30 pm
CURE Holiday Party. 'The best networking in town.' Café George, 300 George Street, New Haven. Save the Date!

Cost-saving discounts for CURE members!
CURE members can now receive discounts on various products and services, such as lab supplies, shipping services, and gases more

Nanoviricides, Inc.
4 Research Drive
Woodbridge, CT 06525

Website: http://www.nanoviricides.com/

Anil R. Diwan, Ph.D., President - info@nanoviricides.com

General Information

NanoViricides, Inc. is publicly traded (symbol: NNVC). We are developing nanomedicines against viruses. A nanoviricide™ is a nanomedicine that uses virus specific ligands to seek out a given target virus and is designed to be then capable of enveloping the virus particle and dismantling it.

Our drug candidates against bird flu (H5N1) (AviFluCide™), high path influenzas (FluCide-HP™), and common influenzas with high morbidity (FluCide™) have been demonstrated to possess excellent safety and efficacy in cell culture studies as well as in vivo studies. Our BioShield efforts include development of a novel technology that enables minimal stockpiling and yet rapid response against novel (i.e. not previously known) pathogens in the field. Our Preparedness efforts include development of a few highly effective, broad-spectrum nanoviricides that work against different types of viruses, enabling simple stockpiling and supply chain management globally despite terrain, weather, and resources limitations. The nanoviricides technology is capable of attacking many different families of viruses.

Our virus targets also include Hepatitis C, HIV, Herpes Simplex, as well as neglected tropical diseases of global importance such as Rabies, Dengue virus, Rift Valley virus, West Nile virus, among others.